On the 12th of January 2006, the European Commission approved Teizeild as the first disease-modifying treatment in Europe, aimed at delaying the onset of clinical type 1 diabetes in individuals with early-stage disease.
It marks a paradigm shift – not just in treatment, but in how we approach prevention and early action.
Early detection is essential to identifying individuals at risk and unlocking the full potential of emerging therapies. Without early screening, these innovations cannot reach the people who would benefit most – especially children and young adults in high-risk groups.
At DiaUnion, we continue to build real-world experience with early detection in Sweden and Denmark, with more than 6,000 individuals already tested in Region Skåne and Region Hovedstaden. Our goal is to support the implementation of national early detection programmes that can help delay disease onset and improve long-term outcomes.
As part of the Alliance for Early T1D Detection (Alliancen for T1Dlig Opsporing), we will bring this agenda to the highest political level at our upcoming conference at the Danish Parliament (Christiansborg) on 13 April 2026.
This is a turning point for the type 1 diabetes community – and a clear call to move early detection from research to real-world healthcare!
🔗 Read the full press release HERE
